Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05803551 · ClinicalTrials.gov registry record · Phase 2
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
A Phase 2 study of Depression, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05803551: Recruiting Phase 2 study of Depression, sponsored by Mayo Clinic.
NCT05803551 is a Phase 2 study of Depression that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05803551, a Phase 2 study of Depression, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).
Primary Outcome
Evaluated by Patient Health Questionnaire-9 (PHQ-9) used to assess degree of depression severity rating symptoms on a scale of 0=not at all, 3=nearly everyday. Higher score indicates greater depression severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketamine Hydrochloride
Study Locations (1)
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05803551 shows while recruiting
NCT05803551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05803551 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05803551 about?
NCT05803551 is a clinical study titled "A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients". The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).
What is the current status of trial NCT05803551?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-07-07. Estimated completion is 2026-12.
What conditions does trial NCT05803551 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT05803551?
The interventions under investigation include: Placebo (DRUG), Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05803551?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05803551 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05803551's enrollment target sits among peer trials
50 468th of 679 higher than 199 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy